

Case Report

A Unique Case of *Gordonia bronchialis* Pneumonia

Ricardo Quita^{a,*}, Beatriz Ferraz^a, Bruno Silva^a, Nuno Faria^a, Catarina Dias^a, Hugo Cruz^b

^a Centro Hospitalar e Universitário do Porto, Serviço de Pneumologia, Porto, Portugal

^b Centro Hospitalar e Universitário do Porto, Serviço de Microbiologia, Porto, Portugal



Gordonia species are gram positive, catalase positive, partially acid-fast aerobic actinomycetes that belong to the genus *Gordonia*.¹ Most of the species within *Gordonia* genus, have been isolated from environmental sources such as soil, farm animals and water.^{1–3} *Gordonia bronchialis* (*G. bronchialis*) was originally isolated from human clinical specimens.^{2,5} Although they rarely cause infection in humans,^{1,4} it is believed that their transmission is primarily through the respiratory inhalation of bacteria.² A number of case reports have been published in the medical literature, but to

our knowledge this is the first report of pneumonia caused by *G. bronchialis*.

78-Year-old male, smoker, with multiple comorbidities, including combined pulmonary fibrosis and emphysema (CPFE) and stage 4 small cell lung carcinoma (SCLC) under treatment with carboplatine/etoposide (CT), presented at the Oncology follow-up visit with complaints of asthenia and increased bronchorrhea. The patient did not present fever or respiratory insufficiency, however there was an increase in inflammatory markers. The follow-up chest computed




Fig. 1. (B) Computed tomography of the chest (lung window) showing opacification on the left superior lung lobe (red arrow) not previously present (A). Computed tomography of the chest (lung window) showing lung carcinoma in the left inferior lobe (yellow arrowhead) before (C) and at the time (D) of reported symptoms.

* Corresponding author.
E-mail address: quitaricardo@gmail.com (R. Quita).

tomography (CT) scan showed a positive response to CTx (decrease in size of carcinoma), but a new opacification on the left superior lung lobe with areas of mucoid impaction and cavitation (Fig. 1).

To study the aetiology of this lesion, flexible bronchoscopy was performed. The patient started empirical antimicrobial therapy with amoxicillin–clavulanic acid 875 mg/125 mg every 12 h for 7 days and CTx was suspended. Routine bronchoalveolar lavage (BAL) bacterial [cut-off $\geq 10^4$ colony forming units (CFU)/mL] and fungal cultures were negative. Detection of *Mycobacterium tuberculosis* complex by real-time polymerase chain reaction (RT-PCR) using Xpert® MTB/RIF Ultra (Cepheid) was also negative. Mycobacteriological culture on Löwenstein-Jensen medium revealed the presence of pigmented, dry and raised colonies, later identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using VITEK® MS (bioMérieux) as *G. bronchialis*. Identification was confirmed by 16S rRNA gene sequencing. As there are no standardized laboratory methods for aerobic actinomycetes other than *Nocardia* species, antimicrobial susceptibility testing (AST) was not performed. Despite a positive clinical (resolution of bronchorrhea) and analytical response to empirical antibiotics, 2 months after, the overall status worsened significantly and it was decided best supportive care.

G. bronchialis has only recently been associated with infection in humans. In the past, *G. bronchialis* infections were probably underdiagnosed due not only to the specific biological features of aerobic actinomycetes, but also to the difficulties in achieving species-level identification using conventional laboratory methods. In fact, due to its fastidious and slow-growing nature, *G. bronchialis* is generally unable to grow in routine bacterial cultures, which was exactly what happened in our case, where the bacterial BAL culture was ruled out as normal respiratory microflora. With the improved accuracy of laboratory identification methods, it is likely that the number of identified infections due to *G. bronchialis* will rise. To our knowledge, this is the first case report of *G. bronchialis* pneumonia. Currently, there are no standardized treatment guidelines for

Gordonia infections. The choice and duration of antimicrobial therapy are often empirical, but should be adjusted based on patient individual response.

Participation

All authors confirm that they have participated actively in the preparation of this article.

Funding

No funding to declare.

Conflict of interest

None to be declare.

References

1. Ramanan P, Deziel PJ, Wengenack NL. *Gordonia* bacteremia. J Clin Microbiol. 2013;51:3443–7. <http://dx.doi.org/10.1128/JCM.01449-13>. Epub 2013 Jul 24. PMID: 23884999; PMCID: PMC3811652.
2. Bartolomé-Álvarez J, Sáez-Nieto JA, Escudero-Jiménez A, Barba-Rodríguez N, Galán-Ros J, Carrasco G, et al. Cutaneous abscess due to *Gordonia bronchialis*: case report and literature review. Rev Esp Quimioter. 2016;29:170–3. Epub 2016 Mar 26. PMID: 27015823.
3. Blanc V, Dalle M, Markarian A, Debonne MV, Duplay E, Rodriguez-Nava V, et al. *Gordonia terrae*: a difficult-to-diagnose emerging pathogen? J Clin Microbiol. 2007;45:1076–7. <http://dx.doi.org/10.1128/JCM.02394-06>. Epub 2006 Dec 27. PMID: 17192419; PMCID: PMC1829133.
4. Arenskötter M, Bröker D, Steinbüchel A. Biology of the metabolically diverse genus *Gordonia*. Appl Environ Microbiol. 2004;70:3195–204. <http://dx.doi.org/10.1128/AEM.70.6.3195-3204.2004>. PMID: 15184112; PMCID: PMC427784.
5. Tsukamura M. Proposal of a new genus, *Gordonia*, for slightly acid-fast organisms occurring in sputa of patients with pulmonary disease and in soil. J Gen Microbiol. 1971;68:15–26. <http://dx.doi.org/10.1099/00221287-68-1-15>. PMID: 4109926.